Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Who can join
Ages 3 to 99 · All sexes · Healthy volunteers welcome
Full eligibility criteria
* INCLUSION CRITERIA: Arms 1-5 (NCC): 1. Aged 3 years and older. 2. Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document. 3. Patients with proven or likely NCC Arm 6 (Endemic Exposures): 1. Patient with epidemiologic history compatible with possible exposure to NCC 2. Aged 18 years and older. EXCLUSION CRITERIA: Not applicable
About the study
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care....
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Participants: 500 · Started: Oct 7, 1985
Contact the study team
- Perla M Adames Castillo, R.N. · Phone: (301) 402-8495
- Elise M O'Connell, M.D. · Phone: (301) 761-5413
Official record on ClinicalTrials.gov — NCT00001205
Locations in the U.S.
| Maryland | National Institutes of Health Clinical Center, Bethesda |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.